Abstract
These findings identify a heretofore unrecognized link between the Chk1 and STAT3 pathways and suggest that Chk1 pathway inhibitors warrant attention as novel and potent candidate STAT3 antagonists in myeloma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have